findmyKOL

Scott Silliman, MD

Basic profile

University of North Florida

ORCIDNone on fileNPI↗
✓ Full record
RegionJacksonville, FL · SoutheastSpecialtyNeurologyFocusNeurology
Active KOLfindmyKOL type: RegionalLatest publication2021Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Scott Silliman is a Neurology physician affiliated with University of North Florida. OpenAlex indexes 162 publications with 7,636 citations (h-index 36).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
162publications

Distinct works indexed by OpenAlex.

7,636citations

Total citations across indexed works.

36h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
13companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

580 W 8th St
Ufjp Neurology
Jacksonville, FL 322096533

Telephone

904-244-3960

Registry record last updated 28 Jul 2009.

View the NPPES registry record

Industry payments

13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    55.3%
    Gabapentinoids11.7%
    Gabapentin58%Pregabalin42%
    Part D≥44 patients
    Potassium Channel Blocker5.7%
    Dalfampridine Er88%Ampyra12%
    Part D<11 patients

    + 18 more classes in this area

  • Cancer & immunology

    24.6%
    Other immunosuppressants6.2%
    Dimethyl Fumarate55%Tecfidera45%
    Part D<11 patients
    Other immunostimulants5.3%
    Glatiramer Acetate44%Glatopa29%Copaxone27%
    Part D<11 patients

    + 6 more classes in this area

  • Musculoskeletal

    13.7%
    gamma-Aminobutyric Acid-ergic Agonist9.4%
    Baclofen100%
    Part D≥53 patients
    Central alpha-2 Adrenergic Agonist2.2%
    Tizanidine Hcl100%
    Part D≥14 patients

    + 2 more classes in this area

Where care is delivered (Part B)60.5% facility · 39.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”